Alembic Pharmaceuticals Quarterly Results

Latest Quarter Net Profit
₹334 Cr
QSept 2026
Quarterly Results

Alembic Pharmaceuticals quarterly results. In Sept 2026, Alembic Pharmaceuticals (APLLTD) reported revenue ₹2,619 Cr and net profit ₹334 Cr — revenue +36.5% YoY. For annual financials, live price and key ratios, visit Alembic Pharmaceuticals screener.

APLLTD Quarterly Results — Revenue, Profit & EPS Highlights

Alembic Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View Alembic Pharmaceuticals yearly highs lows for the annual high/low range and current price position.

  • Revenue of ₹2,619 Cr in Sept 2026 (+39.8% vs Mar 2026, +36.5% vs Sept 2025)
  • Net Profit of ₹334 Cr in Sept 2026 (+65.3% vs Mar 2026, +81.5% vs Sept 2025)
  • EBITDA of ₹577 Cr in Sept 2026 (+150.9% vs Mar 2026)
  • Operating Margin of 22.0% in Sept 2026 (+11.0pp vs Mar 2026)
  • Earnings Per Share of ₹17.05 in Sept 2026 (+65.4% vs Mar 2026)

Alembic Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

APLLTD quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 QoQ YoY
Revenue (₹ Cr) 2,619 1,874 2,165 1,919 1,784 39.8% 36.5%
Net Profit (₹ Cr) 334 202 172 184 157 - -
EBITDA (₹ Cr) 577 230 347 324 286 - -
EPS (₹) 17.05 10.31 8.80 9.40 7.98 - -
Operating Margin (%) 22.0% 11.0% 15.0% 17.0% 15.0% - -

APLLTD Share Price Trend — 1-Year Movement Across Quarterly Results

Alembic Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore APLLTD share price data to track price trends across different timeframes.

Profitability Ratios

Profit Margin 12.8%
EBITDA Margin 22.0%
Operating Margin 22.0%
ROE (Annual) 23.6%

Balance Sheet Highlights

Total Assets ₹8,763 Cr
Total Equity ₹5,669 Cr
Current Assets ₹ Cr
Current Liabilities ₹500 Cr

Cash Flow Analysis

Operating Cash Flow ₹783 Cr
Investing Cash Flow ₹-506 Cr
Financing Cash Flow ₹-164 Cr
Net Cash Flow ₹113 Cr

Current Market Data

Current Price ₹1049.60
Exchange NSE
Last Updated Nov 19, 2026

APLLTD vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Alembic Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2026
₹451,074.97 Cr 1900.0 16,617 1,995 +10.6% - 12.0% 228.9
Divis Laboratories
Sept 2026
₹294,139.19 Cr 11178.0 3,770 1,127 +26.3% - 29.9% 263.1
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4611.0 4,111 364 +27.7% +42.2% 8.9% 400.6
Apollo Hospitals
Sept 2026
₹126,832.45 Cr 8738.0 7,673 660 +15.2% - 8.6% 199.4
Laurus Labs
Sept 2026
₹125,946.78 Cr 2306.0 2,219 436 +21.7% - 19.6% 282.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores